NOW Supplements, Ubiquinol 100 mg

Melatonin/nicotinamide mononucleotide/ubiquinol: a cocktail providing superior cardioprotection against ischemia/reperfusion injury in a common co-morbidities modelled rat.

Most Relevant Research

We designed a study with male Wistar rats, aged 22-24 months and induced with type-2 diabetes, to investigate how a combination of three mitochondrial agents—melatonin, nicotinamide mononucleotide (NMN), and ubiquinol—could provide protection against myocardial ischemia/reperfusion (I/R) injury, especially in the context of aging and diabetes.

The rats were split into groups receiving different treatments, including some that received the cocktail of supplements just during the reperfusion phase after inducing I/R injury. Over 28 days leading up to the tests, rats received NMN, while melatonin and ubiquinol were administered as the heart was being revived after ischemia.

The results indicated that the combination therapy notably enhanced heart protection and improved mitochondrial function and biogenesis in these aged diabetic rats. While ubiquinol was an important part of this cocktail, it is essential to view its role as one among several synergistic agents. This points to exciting possibilities for improved heart health strategies, particularly for older individuals with diabetes.

9.5

Indispensable assistant

Most Useful Review

I regularly take ubiquinol every morning after a heart attack. It's proven effective for my heart defect and improves my energy levels and memory significantly. I no longer require other medications as this helps normalise my blood pressure. Although pricier, its benefits make it worthwhile.

Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial.

Most Relevant Research

With a focus on antiphospholipid syndrome (APS), we set out to understand how ubiquinol, a reduced form of coenzyme Q10, influences markers related to blood clotting and inflammation. Our study was a well-structured, randomized, placebo-controlled trial involving 36 patients with APS, where we administered 200 mg of ubiquinol daily for one month.

We found that supplementation with ubiquinol notably improved the function of blood vessels and reduced the expression of prothrombotic and inflammatory markers present in monocytes. This suggests that ubiquinol plays a role in reducing the risk of blood clots by enhancing endothelial function and dampening inflammatory responses.

Moreover, our results revealed a significant decrease in harmful molecules and a shift in mitochondrial dynamics, which could further support cardiovascular health. Notably, we also observed positive changes in specific microRNAs and gene expressions linked to atherosclerosis, reinforcing the multifaceted benefits of this treatment.

In summary, ubiquinol has the potential to serve as a beneficial adjunct therapy for managing the thrombotic risks associated with APS, especially given its lack of significant side effects. Our findings indicate that ubiquinol could be a promising option for patients seeking to improve their overall condition related to blood clotting.

8.3

Improved blood results

Most Useful Review

I took one tablet daily but felt no effect after a month. After increasing to two tablets, I went for a blood donation and the results the next day showed an improvement in my red and white blood cells, which I struggled to raise previously. I feel less tired and my back was healed in a day. I was often emotionally unstable, but now feel more at ease.

Cardiovascular Disease

SCIENTIFIC SCORE

Likely Very Effective

Based on 1 Researches

Ubiquinol reduces HF mortality, boosts exercise

Evaluating the efficacy of ubiquinol in heart failure patients: a systematic review and meta-analysis.

Most Relevant Research

We aimed to understand how ubiquinol, also known as coenzyme Q10 (CoQ-10), can impact those suffering from heart failure (HF). To do this, we conducted a thorough review of existing studies, searching databases like MEDLINE and the Cochrane Library for relevant literature.

Throughout our evaluation, we focused on key outcomes: whether CoQ-10 could reduce HF-related mortality, improve patients' exercise capacity, and affect the left ventricular ejection fraction (LVEF). Our analysis included findings from 16 different studies that provided intriguing insights.

Notably, we observed that CoQ-10 was effective in reducing HF-related mortality by an impressive 40%. Additionally, patients taking CoQ-10 reported enhanced exercise capacity, which is crucial for improving their quality of life. However, when it came to the left ventricular ejection fraction, the results were less clear; we found no significant difference, though we acknowledge that further research is needed to fully explore its potential effects in this area.

In summary, CoQ-10 shows promise in supporting heart failure patients by reducing mortality and boosting exercise capacity, but its role related to LVEF still warrants additional exploration.

9.5

Cellular defence

Most Useful Review

Ubiquinol, the active form of coenzyme Q10, offers better bioavailability, essential for cardiovascular function and overall health, particularly as we age.